Compare Entegris Inc (ENTG) vs Eli Lilly And Co (LLY) Price & Performance

ENTG trades at $144.21, down 5.17% over 24 hours, with a bullish technical outlook from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with $0.93 EPS, driven by AI-related semiconductor demand. Financials show a net income margin of 9.18% and positive operating cash flow of $695.40M in 2025, though valuation ratios like a P/E of 75.11 appear elevated.

Outlook remains positive due to robust earnings growth and AI tailwinds, but high valuation and competitive pressures pose risks. Analyst consensus is bullish with a $188.67 price target, suggesting 31% upside, supported by institutional buying interest and strong media sentiment from recent news highlights.

Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.

Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.